21:46 , Jan 17, 2019 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 4Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
02:37 , Jan 11, 2014 |  BC Extra  |  Financial News

Intercept jumps again

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) continued to surge after Thursday's positive data surprise. The stock jumped a further $169.96 (62%) to $445.83 on Friday, which translates to a $3.3 billion gain in market cap for a...
08:00 , Feb 28, 2013 |  BC Innovations  |  Tools & Techniques

Cardiomyocytes acting like adults

A collaboration between Sanford-Burnham Medical Research Institute and The Johns Hopkins University School of Medicine cardiology teams has developed a model for arrhythmogenic right ventricular dysplasia/cardiomyopathy that for the first time is able to replicate...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Company News

Dainippon Sumitomo cancer news

Dainippon said it will establish the DSP Cancer Institute for cancer R&D. Chiang Li, who is president, CEO and CMO of Dainippon's Boston Biomedical Inc. subsidiary, will head the institute, which Dainippon said will be...
07:00 , Apr 4, 2011 |  BioCentury  |  Finance

ASCO and Beyond

The second quarter docket is full of clinical and regulatory milestones, as well as early reports of sales for a number of newly launched products. Foremost among the events this quarter is the American Society...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

NGX-4010 regulatory update

NeurogesX Inc. (NASDAQ:NGSX), San Carlos, Calif.   Product: NGX-4010   Business: Neurology   NeurogesX submitted a response to EMEA's Day 120 questions on an MAA for NGX-4010 to treat peripheral neuropathic pain. The company did...
07:00 , Sep 29, 2008 |  BioCentury  |  Finance

Ebb & Flow

Sequenom (NASDAQ:SQNM) has more than quadrupled its market cap to $1.6 billion from $350 million since early June, when the company released initial data on its Down syndrome test. The $1.2 billion uptick equates to...
04:50 , Sep 25, 2008 |  BC Extra  |  Company News

NeurogesX down after response to EMEA

NeurogesX (NASDAQ:NGSX) fell $0.25 (10%) to $2.33 on Wednesday after announcing it submitted a response to EMEA's Day 120 questions on an MAA for NGX-4010 to treat peripheral neuropathic pain. The company did not disclose...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

NGX-4010: Phase III data

Previously reported data from the placebo-controlled, double-blind Phase III C107 trial were published in Neurology and showed that NGX-4010 met the primary endpoint of significantly reduced pain (see BioCentury, Feb. 13, 2006). Mean pain reductions...